The Interplay between PP2A and microRNAs in Leukemia

Frontiers in Oncology
P P Ruvolo

Abstract

Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase family whose members have been implicated in tumor suppression in many cancer models. In many cancers, loss of PP2A activity has been associated with tumorigenesis and drug resistance. Loss of PP2A results in failure to turn off survival signaling cascades that drive drug resistance such as those regulated by protein kinase B. PP2A is responsible for modulating function and controlling expression of tumor suppressors such as p53 and oncogenes such as BCL2 and MYC. Thus, PP2A has diverse functions regulating cell survival. The importance of microRNAs (miRs) is emerging in cancer biology. A role for miR regulation of PP2A is not well understood; however, recent studies suggest a number of clinically significant miRs such as miR-155 and miR-19 may include PP2A targets. We have recently found that a PP2A B subunit (B55α) can regulate a number of miRs in acute myeloid leukemia cells. The identification of a miR/PP2A axis represents a novel regulatory pathway in cellular homeostasis. The ability of miRs to suppress specific PP2A targets and for PP2A to control such miRs can add an extra level of control in signaling that could be used as a rheostat for many signaling cas...Continue Reading

References

Apr 1, 1991·Molecular and Cellular Biology·S I YangM C Mumby
Nov 3, 1995·The Journal of Biological Chemistry·B McCright, D M Virshup
Nov 20, 1998·Molecular and Cellular Biology·K P MullaneB Schaffhausen
Mar 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Adam M SilversteinMarc C Mumby
May 29, 2002·Oncogene·Barbara HoffmanDan A Liebermann
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Sep 15, 2004·The Journal of Biological Chemistry·Stefan StrackLisa Gomez
Jun 10, 2005·Nature·Lin HeScott M Hammond
Mar 22, 2006·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonCarlo M Croce
Oct 10, 2006·Oncogene·G A Calin, C M Croce
Oct 31, 2006·Trends in Molecular Medicine·Ramiro GarzonCarlo M Croce
Aug 21, 2007·Best Practice & Research. Clinical Haematology·George A CalinCarlo M Croce
Dec 11, 2007·Nature Genetics·Tsung-Cheng ChangJoshua T Mendell
Jan 24, 2008·Cancer Metastasis Reviews·Danilo Perrotti, Paolo Neviani
Feb 23, 2008·Trends in Biochemical Sciences·Veerle JanssensJozef Goris
Aug 12, 2008·Current Pharmaceutical Design·Elisa Barbarotto, George A Calin
Aug 12, 2008·Seminars in Oncology·Claudia SchollStefan Fröhling
Oct 30, 2008·The Journal of Biological Chemistry·Vivian R RuvoloPeter P Ruvolo
Dec 11, 2008·Proceedings of the National Academy of Sciences of the United States of America·Baltazar D AgudaClay B Marsh
Mar 25, 2009·Journal of Translational Medicine·Jiaqiang RenDavid F Stroncek
Apr 11, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ryan M O'ConnellDavid Baltimore
May 15, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Teng XuShi-Mei Zhuang
May 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Sheng WeiAlan List
Jun 6, 2009·Cell Death and Differentiation·R I AqeilanC M Croce
Nov 4, 2009·Leukemia & Lymphoma·Aina PonsMariano Monzo
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Queenie W-L WongNathalie Wong
Jan 30, 2010·Blood Cells, Molecules & Diseases·Yungui WangJie Jin

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.